SARTORIUS STED BIO (EPA:DIM) | Finanzwire

Basculer en Français

8296	Companies
114902	Keywords
55332	Articles
62460	Press releases

Home
Companies
SARTORIUS STED BIO

BRIEF

published on 08/02/2024 at 12:27, 3 months 19 days ago

Sartorius Stedim Biotech Announces Share and Voting Rights Update

Voting Rights Shares Regulatory Compliance Sartorius Stedim Biotech Issued Capital
PRESS RELEASE

published on 08/02/2024 at 12:23, 3 months 19 days ago

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA declares the total number of shares and voting rights, as of July 31, 2024, in compliance with legal requirements

Voting Rights Déclaration Shares Sartorius Stedim Biotech SA July 31 2024
PRESS RELEASE

published on 08/02/2024 at 12:22, 3 months 19 days ago

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA declares the number of shares and voting rights in their issued capital. Details in the announcement

Voting Rights Shares AMF Sartorius Stedim Biotech SA French Regulatory News
BRIEF

published on 07/19/2024 at 09:55, 4 months 2 days ago

Sartorius Stedim Biotech SA: Provision of financial documents

Financial Results Investors Sartorius Stedim Biotech First Half Of 2024 Documents Available
PRESS RELEASE

published on 07/19/2024 at 09:51, 4 months 2 days ago

Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech Group releases first-half 2024 results report with business development and financial statements. Leading biopharmaceutical partner based in Aubagne, France

Financial Statements Biopharmaceutical Industry Sartorius Stedim Biotech Group First-half 2024 Results Aubagne
PRESS RELEASE

published on 07/19/2024 at 09:50, 4 months 2 days ago

Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech SA releases information on the availability of documents, including first half 2024 results and financial statements

Financial Results Investor Relations Sartorius Stedim Biotech Biopharmaceutical Industry Document Availability
PRESS RELEASE

published on 07/19/2024 at 09:37, 4 months 2 days ago

Half yearly financial reports and audit reports/limited reviews
PRESS RELEASE

published on 07/18/2024 at 18:30, 4 months 2 days ago

Half-year results 2024 of SartoriusStedimBiotech
Sartorius Stedim Biotech reports half-year results for 2024 with sales revenue of 1,373 million euros and a cautious outlook for the year ahead due to market volatility

Volatility Sartorius Stedim Biotech Sales Revenue Outlook Half-year Results
BRIEF

published on 07/18/2024 at 18:26, 4 months 2 days ago

Sartorius Stedim Biotech Updates Guidance and Shares H1 2024 Results

Financial Results Sartorius Stedim Biotech H1 2024 Fiscal Guidance Life Science Sector
PRESS RELEASE

published on 07/18/2024 at 18:21, 4 months 2 days ago

Sartorius Stedim Biotech SA: Sartorius Stedim Biotech adjusts its guidance for fiscal year 2024 and presents results for H1 2024
Sartorius Stedim Biotech adjusts fiscal year 2024 guidance with positive sales trend in H1 2024 amid volatile market. Company's key financials and outlook disclosed

Fiscal Year 2024 Sartorius Stedim Biotech Outlook Sales Trend Key Financial Indicators

Accesswire

Published on 11/21/2024 at 13:30, 13 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 13 minutes ago

Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 43 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 43 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 43 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 13:15, 28 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 8 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 28 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 37 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 43 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 45 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 23 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 19 hours 58 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 19 hours 58 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 5 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE